NCT06407596

Brief Summary

Background: Hemiplegic shoulder pain is one of the most common complications after a stroke. There are many treatment strategies for this complication. High-intensity laser therapy (HILT) is a new treatment option, and we aimed to compare the effectiveness of conventional electrotherapy agents and HILT in this study. Patients and methods: Participants (N = 42) were randomized into the HILT (n = 21) and TENS+US (n = 21) groups. Group 1 received 3 sessions of HILT per week for 3 weeks in addition to a therapeutic exercise program that performed 5 sessions per week for 3 weeks. Group 2 received conventional physical therapy and a therapeutic exercise program for HSP of 5 sessions per week for 3 weeks. Patients were assessed before and after treatment on the on the 6th week for radiological evaluation with ultrasonography and for clinical parameters with VAS, AMAT, MRS, and FIQ scores.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2023

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 29, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 9, 2024

Completed
Last Updated

May 9, 2024

Status Verified

May 1, 2024

Enrollment Period

8 months

First QC Date

March 29, 2024

Last Update Submit

May 6, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • visual analog scale

    pain level, between 0-10, 0 is no pain, 10 is very severe pain

    before treatment(baseline), after treatment

  • arm motor ability test

    this scale asses the upper extremity motor function improvement and daily living activity level , between 0 is the worst score, mean is cant do/use, 5 is the best score.(between 0-5)

    before treatment(baseline), after treatment

  • functional indepandance measures

    functional capacity assessment scale;and despite indepandance of daily living activity 0-126, high score is better function

    before treatment(baseline), after treatment

  • modified ranking scale

    determines the patient's addiction level and evaluates disability; the score is between 0 and 6, where 0 is complete well-being, 5 is very severe disorder and 6 is full dependency

    before treatment(baseline), after treatment

Secondary Outcomes (1)

  • ultrasonographic imaging

    before treatment(baseline), after treatment

Study Arms (2)

group 1: high intensive laser

EXPERIMENTAL

HILT was applied 3 times per week, totaling 9 sessions for three weeks.

Device: high intensity laser

group 2: TENS+Ultrasound

EXPERIMENTAL

tens+us used combined. 5 times per week. total 15 sessions for three weeks

Device: tens+us

Interventions

3 times per week, for 9 sessions

group 1: high intensive laser
tens+usDEVICE

5 times per week, total 15 sessions for 3 weeks

group 2: TENS+Ultrasound

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed case of HSP,
  • Age ≥18,
  • First-ever unilateral stroke,
  • Visual analog scale (VAS) ≥30 mm,
  • Time since stroke ≥6 months,
  • Time since last local intervention treatment \>6 months.

You may not qualify if:

  • A history of shoulder pain prior to stroke;
  • An unstable medical condition or uncontrolled systemic diseases (such as respiratory failure, congestive heart failure, liver and kidney dysfunction, or any other disorders affecting neuromuscular function);
  • Bilateral hemiplegia;
  • Cardiac pacemakers;
  • Disturbance of awareness, severe visual and cognitive impairment, Mini-Mental State Examination score: \<23 points

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara City Hospital

Ankara, Çankaya, 06800, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Hemiplegia

Condition Hierarchy (Ancestors)

ParalysisNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 29, 2024

First Posted

May 9, 2024

Study Start

June 1, 2022

Primary Completion

February 1, 2023

Study Completion

August 30, 2023

Last Updated

May 9, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations